Financial Comparison: H-CYTE (OTCMKTS:HCYTD) & Beauty Health (NASDAQ:SKIN)

Beauty Health (NASDAQ:SKIN) and H-CYTE (OTCMKTS:HCYTD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Insider & Institutional Ownership

93.3% of Beauty Health shares are held by institutional investors. 41.0% of Beauty Health shares are held by company insiders. Comparatively, 5.2% of H-CYTE shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Beauty Health and H-CYTE”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beauty Health	$398.00 million	0.51	-$100.12 million	($0.83)	-1.96
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A

H-CYTE has lower revenue, but higher earnings than Beauty Health.

Profitability

This table compares Beauty Health and H-CYTE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beauty Health	-22.86%	-4.57%	-0.37%
H-CYTE	-450.40%	N/A	-777.68%

Analyst Ratings

This is a summary of current ratings and price targets for Beauty Health and H-CYTE, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beauty Health	3	7	1	0	1.82
H-CYTE	0	0	0	0	0.00

Beauty Health presently has a consensus target price of $2.46, suggesting a potential upside of 50.82%. Given Beauty Health’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Beauty Health is more favorable than H-CYTE.

Risk and Volatility

Beauty Health has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, H-CYTE has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

Summary

Beauty Health beats H-CYTE on 9 of the 12 factors compared between the two stocks.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.